Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
alnylam pharmaceuticals
6
×
biotech
6
×
boston blog main
clinical trials
6
×
life sciences
national blog main
national top stories
new york blog main
new york top stories
boston top stories
fda
rna interference
amgen
deals
novartis
regeneron pharmaceuticals
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
akouos
alexion pharmaceuticals
alirocumab
boston
boulder/denver blog main
boulder/denver top stories
cancer
detroit blog main
detroit top stories
drugs
evolocumab
hepatitis b
hereditary transthyretin amyloidosis
inclisiran
indiana blog main
indiana top stories
national
new york
patisiran
pcsk9 inhibitors
What
drug
medicines
new
alnylam
bio
brings
cholesterol
deal
fda
medco
patients
pharmaceuticals
rna
roundup
acquire
acquisitions
advantages
ago
agreed
announced
approve
awaits
bar
based
billion
biological
cash
caught
causing
ceo
collabs
company
compound
covid
crossed
daniel
data
decades
decision
dicerna
Language
unset
Current search:
biotech
×
" clinical trials "
×
" alnylam pharmaceuticals "
×
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
Novartis to Acquire MedCo and FDA-Ready Cholesterol Drug for $9.7B
@xconomy.com
4 years ago
Roche to Pay Dicerna Pharma $200M to Team Up on Hepatitis B Drug
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
5 years ago
MedCo Touts New Data for Long-Lasting Heart Drug as Reckoning Looms
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision